Skip to content

Trial Summary

A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

Acronym:

AMG 510

ACTRN/NCT /ethics:

NCT03600883

Scientific title:

A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18+ years
SexBoth
Tumour StreamSolid tumors
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2018-08-27
Anticipated End Date-

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6410
Principal InvestigatorProfessor Tim Price
Recruitment StatusCompleted